

Practitioner's Docket No. 2004DE102

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Thomas Metz et al.

Application No.: 10/587,694

Group No.:

Filed: July 27, 2006

For: 2, 4-Dioxopyrimidine-based mesoionic pigments

Commissioner for Patent P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10\*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

\*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

## Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1.		Enclosures accompanying this Information Disclosure Statement are:  1a.
2.		This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3.	$\boxtimes$	This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4.		This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5.		This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6.		This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

Applicant Thomas Metz et al.: Serial No. 10/587,694 Page 3

7.	The English language documents identified by reference in the
	TRANSLATION Section of the foreign patents list of the attached
	PTO/SB/08A Form are believed to be a concise statement, or the
	equivalent or substantial equivalent to the foreign language documents
	cited in the attached Form PTO/SB/08A.

Respectfully submitted,

Anthony A. Bisulca
Registration No. 40,913

# **CUSTOMER NO. 25,255**

Clariant Corporation Industrial Property Department 4000 Monroe Road Charlotte, North Carolina 28205 Telephone: 704/331-7151

Telephone: 704/331-7151 Facsimile: 704/331-7707

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651 0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork recedent the end of the parents are the		Complete if Known				
Substitute for Form 1449/PTO				Application Number	10/587,694	
INFOE	MATION DI	SCI	OSLIDE	Filing Date	July 27, 2006	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Thomas Metz et al.	
				Art Unit		
			sary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	2004DE102	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
IIIIuais	110.	Number – Kind Code 2 (If known)				
	AA	4,525,591	6/25/1985	Lotsch et al.		
	AB	6,872,245	3/29/2005	Grimm et al.		
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	ΑI					
	AJ					
	AK					
	AL					
<del></del>	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Translation	т6		
initials*	No. '	Country Code <sup>3</sup> - Number <sup>4</sup> – Kind Code <sup>5 (if known)</sup>	MM-DD-YYYY					
_	BA							
	ВВ							
	ВС							
	BD							

Examiner	Date	,
Signature	Cons	sidered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST, 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O, Box 1450, Alexandria, MA 22313-1450.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/PTO				Complete if Known		
				Application Number	10/587,694	
INICOD	MATION I	אפרו ר	GIIDE	Filing Date	July 27, 2006	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Thomas Metz et al.	
				Art Unit		
				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2004DE102	

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	PCT International Search Report for PCT/EP2005/000305, mailed 5/20/2005	
	СВ	English Translation of the PCT International Preliminary Report on Patentability, mailed 10/12/2006.	
	СС	Friedrichsen et al., "Six-membered Mesoionic Heterocycles of the m-Quinodimethane Dianion Type," pp. 1083-1148, Heterocycles, Vol. 19, No. 6; 1982	
	CD	Plug et al., "Mesionic pyridopyrimidinylium and pyridooxazinylium olates and Non-Mesoionic Pyridopyrimidinones. Structures in Solid State, Solutions and Matrices," J. Chem. Soc. Perkin Trans. 2, pp 2096-2108; 2000	
	CE	Hisano et al., "Reaction of Aromatic", N-Oxides with Dipolarophiles. IV Factors Affecting the 1,3-Cycloaddition of Pyridine 1-Oxide with Phenyl Isocyanates," Chem. Phar. Bull. Vol. 29, pp 3706-3712; 1981	
	CF	Laackmann et al., "Bis-(Pyrimidinium olates)," Tetrahedron, Vol. 52, No. 15, pp. 5475-5486; 1996	
	CG		
	СН		
Examiner		Date	
		2000	

Considered Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O, Box 1450, Alexandria, MA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.